Drug Policy in Latvia

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Healthcare Systems

Background:

• Latvia's pharmaceutical sector is highly regulated, with key institutions like the Ministry of Health and the National Health Service (NHS) overseeing pricing and reimbursement.
• The NHS plays a crucial role in pharmaceutical reimbursement decisions, including health technology assessments and managing positive reimbursement lists for outpatient and inpatient care.

Purpose of the Study:

• To provide a comprehensive overview of Latvia's healthcare system.
• To detail the pricing and reimbursement environment for pharmaceuticals in Latvia.

Main Methods:

• Analysis of regulatory frameworks governing the pharmaceutical sector in Latvia.
• Examination of the reimbursement mechanisms for outpatient and inpatient pharmaceuticals.
• Review of pricing policies, including reference pricing and its revision frequency.

Main Results:

• Pharmaceutical pricing and reimbursement in Latvia are strictly controlled.
• Outpatient drug funding relies heavily on reimbursement, with a tiered system (100%, 75%, 50%) based on illness.
• Inpatient pharmaceuticals are integrated into service costs and provided to patients at no charge.

Conclusions:

• Latvia employs a centralized and regulated approach to pharmaceutical pricing and reimbursement.
• The National Health Service is pivotal in managing drug access and affordability through defined reimbursement lists and categories.
• The system ensures patient access to essential medicines through distinct outpatient and inpatient funding models.